Market dipped. This didn’t flinch.

An what an after-the-bell news drop could mean 🚀

April 10, 2025

Markets pulled back today, but I’ve got something wild for you—this small-cap biotech just dropped big news and it’s holding strong. Could be the calm before a breakout.

Good evening,

Stocks dropped a few percent today, giving some back from their record-setting rally yesterday.

Part of that was a natural pullback after such an incredible gain, but the White House added to the pessimism by saying China’s tariff is actually 145%.

On the other hand, during a cabinet meeting, President Trump refused to rule out an additional extension to his 90-day deferment. “We’ll have to see what happens,” he said.

The selling pressure was too much for my “tactical trade” idea from this morning to achieve liftoff, but I’ve turned my attention to another stock that’s just broken some important news.

Have a look at the chart for Shuttle Pharmaceuticals Holdings, Inc. (SHPH).

The first thing you’ll notice is that even as the market bled this morning, its momentum continued from yesterday…

The stock has been building a huge base from the $.40 level. Every time it has dipped below there, it has come right back up for air.

On the upside, recent resistance has been around $.50 so keep a close eye on any breakouts above that level.

And while the stock has been essentially flat over the past month, it should be on your radar right now because its news release just moments ago could be the catalyst it needs to take off…

The Gaithersburg, Maryland-based company was founded in 2012 by faculty members of Georgetown University Medical Center.

Its CEO, Dr. Anatoly Dritschilo, was the chairman of the Department of Radiation Medicine, and its management, board of directors, and scientific advisors all have impressive backgrounds.

The company’s mission is to develop “novel therapies designed to increase cancer cure rates, prolong patient survival, and improve quality of life.”

Its special focus is on enhancing the effectiveness of radiation therapy (RT).

As I’m sure you know, RT can be very successful at defeating cancer. However, oncologists have to limit their dosing because tissues surrounding the cancer are also sensitive to radiation.

SHPH’s lead candidate, Ropidoxuridine, is an orally-administered cancer radiation sensitizer.

The idea is to reduce the dose of radiation necessary to get control of the cancer, while limiting major complications.

For more on the science behind the candidate, check out this investor presentation.

The company successfully launched a Phase 2 trial in November 2024 for Ropidoxuridine — paired with RT — targeting the most aggressive form of brain tumors: IDH wild-type, methylation negative glioblastoma.

The company has reached at least 43% enrollment and at least 11 patients have received all the planned dosages.

SHPH has received an Orphan Drug Designation from the FDA for Ropidoxuridine, which could grant marketing exclusivity if it gets approved.

The company is also developing inhibitors that it believes could activate the innate immune system after RT. To date, they are still in the pre-clinical stage:

SHPH also has a subsidiary, Shuttle Diagnostics, that is developing the PC-RAD Test — a biomarker blood test that could predict outcomes following RT for localized prostate cancer.

Each year, there are ~268,000 new prostate cancer cases in the U.S., and the global prostate cancer diagnostic market reached $2.83 billion back in 2019.

According to the company, “The key unmet need of the diagnostic market is having a predictive, minimally invasive blood test that provides the clinician and patient with a measurement of the potential success of radiation therapy for their cancer treatment.”

SHPH has an exclusive agreement with Georgetown University to advance the test.

In addition, SHPH has a sponsored research agreement with the University of California, San Francisco to advance PSMA-B as a potential diagnostic and therapeutic for metastatic prostate cancer.

The company released a detailed announcement just this evening that it filed a provisional patent application related to this diagnostic.

As you do your own research on SHPH, be sure to check out this shareholder letter/2024 annual report, this fall 2024 investor presentation, and the company website.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: SHPH has been hugging the flatline for the past month, and the news it just released about its diagnostic that it hopes will tap into the multi-billion-dollar prostate cancer diagnostic sector could send it jumping.

This is an urgent trade idea, so be sure to get it on your radar ASAP. If this one jumps, it could soar. Stay tuned!

To Your Success,

Jeff Bishop

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received forty thousand dollars (cash) from IR Agency for advertising Shuttle Pharmaceuticals Holdings for a one day marketing program on April 10, 2025. It might seem obvious, but while our client claims not to own any shares in Shuttle Pharmaceuticals Holdings, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Shuttle Pharmaceuticals Holdings might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.